C‐Met amplification is a mechanism of acquired resistance to EGFR‐TKIs, which was reported in about 20% of NSCLC cases following EGFR‐TKI treatment.[19] Patients with c-MET amplification may derive clinical benefits from c-MET inhibitor cabozantinib.[20] The combination of 2 TKIs, cabozantinib and osimertinib was used as third-line treatment, and SD was obtained for 3 months. The gene discussed is MET; the disease is non-small cell lung carcinoma.